Stability indicating hplc method development and validation for simultaneous estimation of dapagliflozin and metformin tablet dosage form
Abstract
Objectives: The objective of this study was to developed and validated for the routine analysis of dapagliflozin (DAPA) and metformin (MET) in API and tablet dosage forms. Methods: The estimation of DAPA and MET was accomplished with C18 column (4.6 × 250 mm and 5 μm particle size) with DAD detector. The mobile phase consists of Methanol: Water 75:25% v/v of pH-3 adjusted with 0.05% OPA at flow rate of 1 mL/min. The detection wavelength was 233nm, respectively. Results: In the developed method, the retention time of DAPA and MET was found to be 5.099 min and 2.165 min. The reverse phase high performance liquid chromatography method produces linear response that were found in the range of 100–500 μg/mL. The limit of detection and limit of quantification for DAPA were found to be 0.06 μg/mL and 0.1855 μg/mL, respectively and for MET 6.09 μg/mL and 18.45 μg/mL, respectively. Calculated information acquired for both the preliminaries roughly coordinates with the information given by design expert programming which shows the genuineness of the chromatographic condition. Conclusion: The developed method was validated according to the ICH guidelines. The linearity, precision, range, and robustness were within the limits as specified by the ICH guidelines. Hence, the method was found to be simple, accurate, precise, economic, and reproducible.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.